Travere Therapeutics (TVTX) Tops Q1 EPS by $2.43

Travere Therapeutics (NASDAQ: TVTX) reported Q1 EPS of $1.51, $2.43 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $41.37 million versus the consensus estimate of $44.89 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• S&P 500 above 8,000 in 2026 now looks ambitious, Citi says
• Premarket movers: Oracle surges on AI growth, ACV auctions jumps on $1.9B deal